bpc-157 randomized trial humans Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats | Journal of Orthopaedic Surgery and Research BPC-157 and Its Novel Hybrid
Description
Therefore, we recommend that companies determine their regulatory pathway to market in 2025-2026 and consider pre-subs in 2026 to allow time to take action on any FDA feedback before submitting the premarket submission
Although still in early development, this approach has shown promise for targeting various organ systems
Progress may be gradual, but consistency is what moves the needle
verify current FDA guidance at FDA.gov
